Decreased levels of complex III core protein 1 and complex V β chain in brains from patients with Alzheimer's disease and down syndrome

Cellular and Molecular Life Sciences

Volumn 57, Issue 12, 2000, Pages 1810-1816

  Kim, S H ^a   Vlkolinsky, R ^a   Cairns, N ^b   Lubec, G ^a  

^a UNIVERSITY OF VIENNA   (Austria)

^b KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Alzheimer's disease; ATP synthase; Down syndrome; Mitochondrial electron transport chain; Neurodegenerative disease; Neuronal cell death; Ubiquinol:cytochrome c oxidoreductase

Indexed keywords

BRAIN PROTEIN; CORE PROTEIN; MITOCHONDRIAL ENZYME; PROTEOME; PROTON TRANSPORTING ADENOSINE TRIPHOSPHATASE; REACTIVE OXYGEN METABOLITE; UBIQUINOL CYTOCHROME C REDUCTASE;

ADULT; ALZHEIMER DISEASE; APOPTOSIS; ARTICLE; BETA CHAIN; BRAIN REGION; CONTROLLED STUDY; DEGENERATIVE DISEASE; DOWN SYNDROME; ENERGY METABOLISM; ENZYME DEFECT; FRONTAL CORTEX; HUMAN; HUMAN TISSUE; NERVE CELL NECROSIS; RESPIRATORY CHAIN; TEMPORAL CORTEX;

EID: 0033679409     PISSN: 1420682X     EISSN: None     Source Type: Journal    
DOI: 10.1007/PL00000661     Document Type: Article

References (52)

1. Mitochondria and programmed cell death: Back to the future
2. Why are mitochondria involved in apoptosis? Permeability transition pores and apoptosis as selective mechanisms to eliminate superoxide-producing mitochondria and cell
3. An evaluation of the role of mitochondria in neurodegenerative diseases: Mitochondrial mutations and oxidative pathology, protective nuclear responses, and cell death in neurodegeneration
4. Mitochondrial enzyme deficiencies in Down's syndrome
5. Do defects in mitochondrial energy metabolism underlie the pathology of neurodegenerative diseases?
6. Mitochondrial involvement in Parkinson's disease. Huntington's disease, hereditary spastic paraplegia and Friedreich's ataxia
7. The mitochondrial electron transport and oxidative phosphorylation system
8. Electron transport chain defects in Alzheimer's disease brain
9. Cortical cytochrome oxidase activity is reduced in Alzheimer's disease
10. Human diseases with defects in oxidative phosphorylation. 2. F1F0 ATP-synthase defects in Alzheimer disease revealed by blue native polyacrylamide gel electrophoresis
11. Mitochondrial complex I deficiency in Parkinson's disease
12. Deficiencies in complex I subunits of the respiratory chain in Parkinson's disease
13. Mitochondrial respiratory failure in skeletal muscle from patients with Parkinson's disease and multiple system atrophy
14. The NINCDA-ADRDA work group criteria for the clinical diagnosis of probable Alzheimer's disease
15. The consortium to establish a registry for Alzheimer's disease
16. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding
17. Effect of the protein application mode and the acrylamide concentration on the resolution of protein spots separated by two-dimensional gel electrophoresis
18. Two-dimensional map of human brain proteins
19. Identification of protein by matrix-assisted laser desorption ionization-mass spectroscopy following in-gel digestion in low-salt nonvolatile buffer and simplified peptide recovery
20. Cytochrome oxidase deficiency in Alzheimer's disease
21. Brain cytochrome oxidase in Alzheimer's disease
22. A selective defect of cytochrome c oxidase is present in brain of Alzheimer disease patients
23. Decreased hippocampal metabolic activity in Alzheimer patients is not reflected in the immunoreactivity of cytochrome oxidase subunits
24. Mitochondria function in Parkinson's disease
25. Evidence for a defect in NADH: Ubiquinone oxidoreductase (complex I) in Huntington's disease
26. The role of oxidative stress in Alzheimer disease
27. Reactive oxygen species and their contribution to pathology in Down syndrome
28. Oxidative stress and mitochondrial dysfunction in neurodegeneration
29. Oxidative damage to mitochondrial DNA is increased in Alzheimer's disease
30. Increased nuclear DNA oxidation in the brain in Alzheimer's disease
31. Defective repair of oxidative damage in mitochondrial DNA in Down's syndrome
32. Apoptosis and increased generation of reactive oxygen species in Down's syndrome neurons in vitro
33. Biomarkers of oxidative stress are significantly elevated in Down syndrome
34. Oxidative alterations in Alzheimer's disease
35. Autopsy samples of Alzheimer's cortex show increased peroxidation in vitro
36. Selective increase in lipid peroxidation in the inferior temporal cortex in Alzheimer's disease
37. Neural apoptosis
38. Aging, energy, and oxidative stress in neurodegenerative diseases
39. Mitochondrial respiratory chain inhibitors induce apoptosis
40. Complex I inhibitors induce dose-dependent apoptosis in PC12 cells: Relevance to Parkinson's disease
41. Apoptosis and DNA degradation induced by 1-methyl-4-phenylpyridinium in neurons
42. Origin and functional consequences of the complex I defect in Parkinson's disease
43. Titrating the effects of mitochondrial complex I impairment in the cell physiology
44. Differential display reveals deteriorated mRNA levels of NADH 3 (complex I) in cerebellum of patients with Down syndrome
45. Decreased levels of synaptosomal associated protein 25 in the brain of patients with Down syndrome and Alzheimer's disease
46. Specific inhibitors of vacuolar type H(+)-ATPases induce apoptotic cell death
47. Specific inhibitors of vacuolar type H(+)-ATPase trigger apoptotic cell death of osteoclasts
48. Caspase-3 activation during the process of apoptosis induced by a vacuolar type H(+)-ATPase inhibitor
49. Bafilomycin A1 induces apoptosis in the human pancreatic cancer cell line Capan-1
50. Mitochondria, free radicals and neurodegeneration
51. Energy expenditure in children with Down syndrome: Correcting metabolic rate for movement
52. Decreased resting metabolic rate among persons with Down syndrome